Reality check: Real-world evidence to support therapeutic development in hematologic malignancies
Authors:
Open Access
- 3 March 2022
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 53, 100913
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaBlood, 2017
- Pragmatic TrialsNew England Journal of Medicine, 2016
- Assessing the Gold Standard — Lessons from the History of RCTsNew England Journal of Medicine, 2016
- Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and OpportunitiesClinical Lymphoma Myeloma and Leukemia, 2015
- Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial RegistryThe Oncologist, 2014
- Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phaseCurrent Medical Research and Opinion, 2014
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidenceBritish Journal of Cancer, 2014
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?Bone Marrow Transplantation, 2009
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007